Case reportFolliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin
Section snippets
Case report
A 43-year-old male resented with a 3-month history of a cough with intermittent hemoptysis that did not respond to an initial course of antibiotics. A chest radiograph showed right upper lobe consolidation. Subsequent bronchoscopy showed obstruction of the right upper lobe bronchus with extrinsic compression. Histology was consistent with primary adenocarcinoma of the lung. A staging computed tomography (CT) scan showed this to be a T4N2M0 tumor. He was treated with two cycles of cisplatin and
Discussion
Erlotinib is an EGFR tyrosine kinase inhibitor which acts by targeting the overexpressed EGF receptors on cancer cells.
EGFR is a growth factor receptor that induces cell differentiation and proliferation upon activation through the binding of one of its ligands. The receptor is located at the cell surface and is expressed in the hair follicles, sebaceous glands, epithelium, and the basal layer of the epidermis, where proliferating keratinocytes are located.1, 2 The growth factor receptor is
References (20)
- et al.
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors
Ann Oncol
(2005) - et al.
Cutaneous side-effects of kinase inhibitors and blocking antibodies
Lancet Oncol
(2005) - et al.
Pathophysiology of irradiated skin and breast
Int J Radiat Oncol Biol Phys
(1995) - et al.
Altered proliferation and differentiation of human epidermis in cases of skin fibrosis after radiotherapy
Int J Radiat Oncol Biol Phys
(2002) - et al.
Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients
Ann Oncol
(2007) - et al.
Prognostic factors for acute and late skin reactions in radiotherapy patients
Int J Radiat Oncol Biol Phys
(1996) - et al.
Patient-to-patient variability in the expression of radiation-induced normal tissue injury
Semin Radiat Oncol
(1994) - et al.
Phase II trial of gefitinib in recurrent glioblastoma
J Clin Oncol
(2004) - et al.
The EGF/TGF alpha receptor in skin
J Invest Dermatol
(1990) - et al.
Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials
Ann Oncol
(1997)
Cited by (14)
Erlotinib-induced acneiform rash not affecting previously irradiated skin
2010, Actas Dermo-SifiliograficasHair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapy
2019, Science Translational MedicineMechanisms underlying skin disorders induced by EGFR inhibitors
2015, Molecular and Cellular OncologyCetuximab-induced acneiform eruption sparing a previously irradiated skin area
2014, Medicina Cutanea Ibero-Latino-AmericanaThe great mimickers of rosacea
2014, Cutis
Funding sources: None.
Conflicts of interest: None declared.
Reprints not available from authors.